Related Experiment Videos
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues
Johnna Perdrizet1, Carlos Felipe S Santana2, Thais Senna2
1Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.
Human Vaccines & Immunotherapeutics
|April 28, 2021
Abstract:
This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study "Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants." Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.